|Bid price||178.90||Open price||180.00|
|Ask price||180.50||Prev close||179.50|
Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.
Register now for FREE Vectura Group share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B01D1K48|
|Activites||Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.||Index||FTSE 250|
|Latest Share Price (p)||179.70||Net Gearing (%)||-6.27|
|Market Capitalisation (£m)||722.06||Gross Gearing (%)||24.40|
|Shares in issue (m)||404.52||Debt Ratio||10.20|
|P/E Ratio||198.33||Debt-to-Equity Ratio||0.35|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.32|
|Dividend Yield (%)||0.00||Price to book value||3.25|
|Dividend cover (x)||0.00||ROCE||-0.03|
|Earning per share (p)||0.90||EPS Growth (%)||228.57|
|52 week high / low||183.75 / 113.75||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|07/07/2015||BUY||Dr Trevor Phillips||ED||1,000|
|17/04/2015||EXR||Dr Christopher Blackwell||RES||18,987|
|16/01/2015||EXR||Dr Trevor Phillips||ED||3,133|
|16/01/2015||EXR||Dr Trevor Phillips||ED||208,877|
/* */ RNS Number : 2326U Vectura Group plc 28 July 2015 Vectura Group plc Announces successful pre-IND meeting with the US FDA regarding VR647 Chippenham, UK - 28 July 2015: Vectura Group plc (LSE: VEC; "Vectura"...
/* */ RNS Number : 1034T Vectura Group plc 15 July 2015 Annex DTR3 Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons All relevant boxes should be completed in block...
Andrew Oakley, Financial Director, bought 1,000 shares in the company on the 6th July 2015 at a price of 180.00p. The Director now holds 1,000 shares representing 0.00% of the shares in issue. NOTE: SIP Purchase: Also awarded 1000 matching shares Story provided by StockMarketWire.com Director...
Register now for FREE Vectura Group company news